Huda Y. Zoghbi Sells 1,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Posted by Defense World Staff on Oct 19th, 2023

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Huda Y. Zoghbi sold 1,000 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $850.00, for a total value of $850,000.00. Following the transaction, the director now owns 1,247 shares in the company, valued at approximately $1,059,950. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Regeneron Pharmaceuticals Stock Down 1.3 %

Shares of REGN opened at $826.03 on Thursday. The company has a market capitalization of $89.67 billion, a PE ratio of 21.84, a PEG ratio of 2.52 and a beta of 0.19. Regeneron Pharmaceuticals, Inc. has a 12 month low of $668.00 and a 12 month high of $853.97. The stock’s 50-day moving average price is $826.68 and its two-hundred day moving average price is $783.20. The company has a current ratio of 5.45, a quick ratio of 4.64 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $10.24 EPS for the quarter, topping the consensus estimate of $8.48 by $1.76. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. The firm had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same period in the previous year, the business earned $9.77 EPS. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Welch Group LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $222,000. CX Institutional raised its position in shares of Regeneron Pharmaceuticals by 10.7% in the 3rd quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 30 shares in the last quarter. Strategic Blueprint LLC raised its position in shares of Regeneron Pharmaceuticals by 6.4% in the 3rd quarter. Strategic Blueprint LLC now owns 4,926 shares of the biopharmaceutical company’s stock worth $4,054,000 after acquiring an additional 295 shares in the last quarter. Private Trust Co. NA raised its position in shares of Regeneron Pharmaceuticals by 30.4% in the 3rd quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 94 shares in the last quarter. Finally, Mach 1 Financial Group LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $481,000. 84.15% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on REGN. Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $800.00 to $850.00 and gave the stock a “neutral” rating in a research note on Monday. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $720.00 to $992.00 in a report on Monday, August 21st. StockNews.com assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, October 5th. They issued a “buy” rating on the stock. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $960.00 to $985.00 and gave the company an “outperform” rating in a report on Monday, August 21st. Finally, Oppenheimer raised their target price on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company a “market perform” rating in a report on Monday, August 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $900.96.

Get Our Latest Research Report on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.